Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct;35(10):1059-1075.
doi: 10.14670/HH-18-221. Epub 2020 Apr 23.

Evaluating Trastuzumab in the treatment of HER2 positive breast cancer

Ryan Jaques  1 , Sam Xu  2 , Antonios Matsakas  2
Affiliations
Review

Evaluating Trastuzumab in the treatment of HER2 positive breast cancer

Ryan Jaques et al. Histol Histopathol. 2020 Oct.

Abstract

The transmembrane oncoprotein HER2 is encoded by ERBB2 gene and overexpressed in around 20% of invasive breast cancers. It can be specifically targeted by Trastuzumab (Herceptin®), a humanised IgG1 antibody. Trastuzumab has been regarded as one of the most effective therapeutic drugs targeted to HER2 positive cancers. However, there are drawbacks, notably cardiotoxicity and resistance, which have raised awareness in clinical use. Therefore, understanding the mechanism of action is vital to establish improved therapeutic strategies. Here we evaluate Trastuzumab application in the treatment of HER2 positive breast cancer, focusing on its mechanistic actions and clinical effectiveness. Alternative therapies targeting the HER2 receptor and its downstream anomalies will also be discussed, as these could highlight further targets that could be key to improving clinical outcomes.

PubMed Disclaimer

References

    1. Arnal-Estape A., Tarragona M., Morales M., Guiu M., Nadal C., Massague J. and Gomis R.R. (2010). HER2 silences tumor suppression in breast cancer cells by switching expression of C/EBPss isoforms. Cancer Res. 70, 9927-9936. - PubMed
    1. Arribas J., Baselga J., Pedersen K. and Parra-Palau J.L. (2011). p95HER2 and breast cancer. Cancer Res. 71, 1515-1519. - PubMed
    1. Austin C.D., De Maziere A.M., Pisacane P.I., van Dijk S.M., Eigenbrot C., Sliwkowski M.X., Klumperman J. and Scheller R.H. (2004). Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol. Biol. Cell. 15, 5268-5282. - PMC - PubMed
    1. Awada A., Colomer R., Inoue K., Bondarenko I., Badwe R.A., Demetriou G., Lee S.C., Mehta A.O., Kim S.B., Bachelot T., Goswami C., Deo S., Bose R., Wong A., Xu F., Yao B., Bryce R. and Carey L.A. (2016). Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: The NEfERT-T randomized clinical trial. JAMA Oncol. 2, 1557-1564. - PubMed
    1. Balduzzi S., Mantarro S., Guarneri V., Tagliabue L., Pistotti V., Moja L. and D'Amico R. (2014). Trastuzumab‐containing regimens for metastatic breast cancer. Cochrane Database Syst. Rev. 6, CD006242. - PMC - PubMed

MeSH terms

Grants and funding

LinkOut - more resources